Pulse Biosciences (NASDAQ:PLSE) Reaches New 1-Year High – Time to Buy?

Pulse Biosciences, Inc (NASDAQ:PLSE)’s stock price hit a new 52-week high during trading on Friday . The company traded as high as $28.98 and last traded at $29.6750, with a volume of 60412 shares changing hands. The stock had previously closed at $27.50.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on PLSE shares. Weiss Ratings restated a “sell (d-)” rating on shares of Pulse Biosciences in a report on Tuesday, April 21st. Canaccord Genuity Group initiated coverage on Pulse Biosciences in a research report on Thursday, June 4th. They issued a “buy” rating and a $32.00 price target for the company. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Pulse Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $30.67.

Pulse Biosciences Price Performance

The firm has a market cap of $1.99 billion, a price-to-earnings ratio of -26.05 and a beta of 1.65. The stock’s fifty day moving average price is $24.07 and its 200-day moving average price is $20.04.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings data on Monday, May 4th. The company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.05. The firm had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.25 million. As a group, equities research analysts predict that Pulse Biosciences, Inc will post -1.29 EPS for the current fiscal year.

Insider Buying and Selling at Pulse Biosciences

In other Pulse Biosciences news, CEO Paul A. Laviolette bought 15,000 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was acquired at an average price of $19.69 per share, with a total value of $295,350.00. Following the completion of the transaction, the chief executive officer directly owned 15,000 shares in the company, valued at approximately $295,350. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Robert W. Duggan purchased 660,233 shares of the stock in a transaction dated Monday, May 11th. The shares were acquired at an average price of $19.69 per share, for a total transaction of $12,999,987.77. Following the acquisition, the director directly owned 48,211,433 shares of the company’s stock, valued at $949,283,115.77. This represents a 1.39% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 74.00% of the company’s stock.

Hedge Funds Weigh In On Pulse Biosciences

Large investors have recently made changes to their positions in the business. BNP Paribas Financial Markets increased its stake in shares of Pulse Biosciences by 63.6% in the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock worth $26,000 after acquiring an additional 680 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in Pulse Biosciences by 275.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock valued at $44,000 after purchasing an additional 2,156 shares during the last quarter. Russell Investments Group Ltd. boosted its position in Pulse Biosciences by 13.8% during the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock valued at $70,000 after purchasing an additional 619 shares during the last quarter. The Manufacturers Life Insurance Company purchased a new position in Pulse Biosciences in the second quarter valued at about $158,000. Finally, Brevan Howard Capital Management LP purchased a new position in Pulse Biosciences in the second quarter valued at about $215,000. Institutional investors and hedge funds own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.